Androgen receptor: Difference between revisions

These non-steroidal drugs can normally be administered orally or using a transdermal injection <ref name="NR" /><ref name="SARMs therapy" /> with better compliance. They are not affected by 5α-reductase (limiting their androgenic adverse effects) and aromatase (limiting their estrogenic side effects) <ref name="NR" /><ref name="SARMs therapy" />. Those characteristics help to reduce side effects related to the use of natural androgens. Moreover, the tissue selectivity of these drugs make them a suitable option to treat syndromes and diseases skipping the risk related with the use of TRT <ref name="NR" /><ref name="SARMs therapy" /><ref name="SARMs" />.

Also, some SARMs could be a good option to achieve the improvement in anabolic activity and muscular density obtained by the use of AAs, without the unwanted side effects associated with their androgenic action <ref name="Steroids" />.

Currently, the tissue selectivity of SARMs is still under research <ref name="SARMs" /><ref name="Steroids" /> and there is no consensus in the detailed mechanisms of action. However, there are two features that could explain their biological activity:

*Their non-steroidal composition and the fact that they are unaffected by 5α-reductase <ref name="SARMs therapy" /><ref name="SARMs" /><ref name="Steroids" />, promotes the interaction of AR with tissue-specific coactivators.